| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 05/02/2013 | WO2013063321A1 Wnt/b-catenin inhibitors and methods of use |
| 05/02/2013 | WO2013063312A1 Free psa antibodies as diagnostics, prognostics and therapeutics for prostate cancer |
| 05/02/2013 | WO2013063216A1 5-nonyloxytrptamine and related intracellular ph acidifiers for the treatment and prevention of cancer |
| 05/02/2013 | WO2013063035A1 Biomarkers of cancer |
| 05/02/2013 | WO2013063017A1 Diagnosis and treatment of mesothelioma |
| 05/02/2013 | WO2013063003A1 Method of treating gastrointestinal stromal tumors |
| 05/02/2013 | WO2013063001A1 Therapeutic combinations and methods of treating melanoma |
| 05/02/2013 | WO2013062984A1 Method for treatment of mesothelioma |
| 05/02/2013 | WO2013062365A2 Mutant ctla4 gene transfected t cell and composition including same for anticancer immunotherapy |
| 05/02/2013 | WO2013062349A2 Triticum aestivum lamarck leaf extract or composition containing fractions thereof as active ingredient |
| 05/02/2013 | WO2013062202A1 Mri contrast agent coated with amphoteric ion |
| 05/02/2013 | WO2013062190A1 Cooling composition |
| 05/02/2013 | WO2013062071A1 Piperazine derivative and salt thereof |
| 05/02/2013 | WO2013062050A1 Aqueous gemcitabine solution preparation |
| 05/02/2013 | WO2013061977A1 Heterocycle derivative having pgd2 receptor antagonist activity |
| 05/02/2013 | WO2013061669A1 Benzohydrazide derivative for inducing g2/m phase arrest and cell death |
| 05/02/2013 | WO2013061594A1 Topk peptides and vaccines including the same |
| 05/02/2013 | WO2013061455A1 Novel resveratrol polymerization compound or pharmaceutically acceptable salt thereof |
| 05/02/2013 | WO2013061328A2 Method of treating cancer |
| 05/02/2013 | WO2013061083A2 Therapeutic agents and uses thereof |
| 05/02/2013 | WO2013061080A1 Anticancer pyridopyrazines via the inhibition of fgfr kinases |
| 05/02/2013 | WO2013061077A1 New compounds |
| 05/02/2013 | WO2013061074A1 Quinolines as fgfr kinase modulators |
| 05/02/2013 | WO2013061005A1 Disubstituted 3,4-diamino-3-cyclobutene-1,2-dione compounds for use in the treatment of chemokine-mediated pathologies |
| 05/02/2013 | WO2013061004A1 Novel disubstituted 3,4-diamino-3-cyclobutene-1,2-dione compounds for use in the treatment of chemokine-mediated diseases |
| 05/02/2013 | WO2013060922A1 Rosemary‑extract compositions for treating cancer |
| 05/02/2013 | WO2013060872A1 Anticancer combination therapy |
| 05/02/2013 | WO2013060864A1 Chimeric molecule involving oligomerized fasl extracellular domain |
| 05/02/2013 | WO2013060636A1 6-(4-hydroxy-phenyl)-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| 05/02/2013 | WO2013060305A1 Pharmaceutical composition for elimination of cancer stem cells |
| 05/02/2013 | WO2013060304A1 Solid dispersion of paclitaxel or homologue thereof and preparation method therefor |
| 05/02/2013 | WO2013060303A1 Polypeptides inhibiting neovascularization and uses thereof |
| 05/02/2013 | WO2013060274A1 Derivatives of protoberberine biological alkaloids and use of same inhibiting ulcerative colitis |
| 05/02/2013 | WO2013060230A1 Sirna molecule for inhibiting growth of melanin and application thereof |
| 05/02/2013 | WO2013060179A1 Acyltetrahydro-β-carboline compounds as well as derivatives, applications and preparation methods thereof |
| 05/02/2013 | WO2013060098A1 Kinase inhibitor and method for treatment of related diseases |
| 05/02/2013 | WO2013060052A1 Hypoallergenic recombinant immunotoxin, and preparation method and application thereof |
| 05/02/2013 | WO2013060020A1 Novel small peptide capable of inhibiting new vessels and application thereof |
| 05/02/2013 | WO2013059944A1 Epigenetic regulators and uses thereof |
| 05/02/2013 | WO2013059927A1 Compounds targeting the cell invasion protein complex, their pharmaceutical compositions and methods of use thereof |
| 05/02/2013 | WO2013059898A1 Pharmaceutical compositions containing sesquiterpene lactones belonging to the class of furan heliangolides for the treatment of parasitic infections and tumours |
| 05/02/2013 | WO2013059886A1 Pat-lm1 epitopes and methods for using same |
| 05/02/2013 | WO2013052006A8 Parp-1 inhibitors |
| 05/02/2013 | WO2013036912A3 Amido compounds as rorϒtmodulators and uses thereof |
| 05/02/2013 | WO2013036867A3 Compositions and methods for cancer and cancer stem cell detection and elimination |
| 05/02/2013 | WO2013036850A3 Modulation of midbody derivatives |
| 05/02/2013 | WO2013036543A3 Molecular imaging of cancer cells in vivo |
| 05/02/2013 | WO2013033626A3 Nkp30 receptor targeted therapeutics |
| 05/02/2013 | WO2013028832A3 Inhibitors of nedd8-activating enzyme |
| 05/02/2013 | WO2013020040A3 Radiated cancer cells as a vehicle for cancer nanotherapy |
| 05/02/2013 | WO2013015661A3 Novel prodrugs of 5-(2,4-dihydroxy-5-isopropylphenyl)-n-ethyl-4-(5-methyl1-1,2,4-oxadiazol-3-yl)isoxazole-3-carboxamide |
| 05/02/2013 | WO2012177892A3 Type i interferon mimetics as therapeutics for cancer, viral infections, and multiple sclerosis |
| 05/02/2013 | WO2012061469A3 Crystalline forms of pralatrexate |
| 05/02/2013 | US20130109752 DERIVATIVE OF 18beta-GLYCYRRHETINIC ACID APT TO SUPPRESS CANCER CELLS |
| 05/02/2013 | US20130109724 N-aminopyrrolylmethyltetrahydropyridines as anti-cancer agents |
| 05/02/2013 | US20130109716 N-aminotetrahydroisoquinolines as anti-cancer agents |
| 05/02/2013 | US20130109709 Methods of treating a bruton's tyrosine kinase disease or disorder |
| 05/02/2013 | US20130109668 Azetidine compounds, compositions and methods of use |
| 05/02/2013 | US20130109665 Novel pyrazine derivatives |
| 05/02/2013 | US20130109648 Method for treating a human patient suffering from myeloid neoplasias using 5-aminoimidazole-4-carboxamide |
| 05/02/2013 | US20130109644 Methods for treating cancers using oral formulations of cytidine analogs |
| 05/02/2013 | US20130108672 Pharmaceutical compositions for substituted quinazolinones |
| 05/02/2013 | US20130108650 Actriib binding agents and uses thereof |
| 05/02/2013 | US20130108619 Intravenous immunoglobulin processing, diagnostic, and treatment systems and methods |
| 05/02/2013 | US20130108578 Apo-2 ligand variants and uses thereof |
| 05/02/2013 | CA2853734A1 Methods and compositions related to intracellular neutralization by igg |
| 05/02/2013 | CA2853729A1 Novel compositions and methods for treating cancer |
| 05/02/2013 | CA2853722A1 Inhibiting g protein coupled receptor 6 kinase polypeptides |
| 05/02/2013 | CA2853705A1 Free psa antibodies as diagnostics, prognostics and therapeutics for prostate cancer |
| 05/02/2013 | CA2853669A1 Therapeutic agents and uses thereof |
| 05/02/2013 | CA2853637A1 Monoclonal antibodies and methods of use |
| 05/02/2013 | CA2853501A1 Methyltransferase inhibitors for treating cancer |
| 05/02/2013 | CA2853440A1 Kinase inhibitor and method for treatment of related diseases |
| 05/02/2013 | CA2853390A1 Anticancer pyridopyrazines via the inhibition of fgfr kinases |
| 05/02/2013 | CA2853367A1 New compounds |
| 05/02/2013 | CA2853366A1 Quinolines as fgfr kinase modulators |
| 05/02/2013 | CA2852709A1 Pat-lm1 epitopes and methods for using same |
| 05/02/2013 | CA2852633A1 Topk peptides and vaccines including the same |
| 05/02/2013 | CA2852627A1 Heterocyclic derivative having pgd2 receptor antagonist activity |
| 05/02/2013 | CA2851545A1 Cd44 monoclonal antibody for the treatment of b-cell chronic lymphocytic leukemia and other hematological malignancies |
| 05/02/2013 | CA2850034A1 Therapeutic combinations and methods of treating melanoma |
| 05/02/2013 | CA2849977A1 Disubstituted 3,4-diamino-3-cyclobutene-1,2-dione compounds for use in the treatment of chemokine-mediated pathologies |
| 05/02/2013 | CA2848263A1 Novel disubstituted 3,4-diamino-3-cyclobutene-1,2-dione compounds for use in the treatment of chemokine-mediated diseases |
| 05/01/2013 | EP2586865A2 Recombinant vector for suppressing proliferation of human papillomavirus cell including adenylate cyclase activating polypeptide 1 (pituitary) gene and pharmaceutical composition for treating human papillomavirus |
| 05/01/2013 | EP2586798A2 B-cell reduction using CD37-specific and CD20-specific binding molecules |
| 05/01/2013 | EP2586794A2 Manufacture, Compositions and Uses of Coagulationfactor VIIA Modulator |
| 05/01/2013 | EP2586793A1 Chimeric molecule involving oligomerized FasL extracellular domain |
| 05/01/2013 | EP2586463A1 Pharmaceutical multimeric particles, and manufacturing method for same |
| 05/01/2013 | EP2586453A1 Tumor growth controlling method targeting galactosylceramide expression factor-1 |
| 05/01/2013 | EP2586443A1 Antitumor agent using compounds having kinase inhibitory effect in combination |
| 05/01/2013 | EP2586441A1 Combination of egcg or methylated egcg and a pde inhibitor |
| 05/01/2013 | EP2586425A1 Preparing method of allicin injection and low temperature continuous stirring ultrafiltration device thereof |
| 05/01/2013 | EP2585583A2 Cellular constituents from bacteroides, compositions thereof, and therapeutic methods employing bacteroides or cellular constituents thereof |
| 05/01/2013 | EP2585470A2 Novel fused pyrimidine derivatives for inhd3ition of tyrosine kinase activity |
| 05/01/2013 | EP2585469A1 Benzodioxole or benzodioxepine heterocyclic compounds phosphodiesterase inhibitors |
| 05/01/2013 | EP2585468A1 Pyrrolo- pyrazine derivatives useful as inhibitors of atr kinase |
| 05/01/2013 | EP2585466A1 Polymorphs of osi-906 |
| 05/01/2013 | EP2585465A1 Benzotriazolodiazepine compounds inhibitors of bromodomains |
| 05/01/2013 | EP2585463A1 Beta carboline derivatives useful in the treatment of proliferative disorders |
| 05/01/2013 | EP2585461A1 2,4- diaryl - substituted [1,8]naphthyridines as kinase inhibitors for use against cancer |